For comments, suggestions
Created with Raphaël 2.1.0 11.11.2018 Filing date 09.06.2020 Validation fee payment 31.10.2020 (A1) Patent application published 18.12.2024 AGEPI application filing date 28.02.2025 (T2) Translation of the validated European patent 09.05.2025 11.11.2025 Valid until 12.11.2026 Renewal fee to be paid until 11.11.2038 Patent will expire on

Patent in force


(210)Number of the EPO application18876779
(220)Filing date of the EPO application2018.11.11
(80)EPO patent specification publication (B)EPB nr. 42/2024, 2024.10.16
(110)EPO patent number3706739
(11)Number of the documentMD 3706739 T2
(21)Number of the applicatione 2020 0953
(71)Name(s) of applicant(s), code of the countryBIOHAVEN THERAPEUTICS LTD., US;
(72)Name(s) of inventor(s), code of the countryCORIC Vladimir, US;
BERMAN Robert, US;
BEINER Melissa, US;
L'ITALIEN Gilbert, US;
(73)Name(s) of owner(s), code of the countryBIOHAVEN THERAPEUTICS LTD., US;
(54)Title of the inventionUse of riluzole prodrugs to treat ataxias
(13)Kind-of-document code T2
(51)International Patent Classification A61K 31/428 (2006.01.01); A61K 31/427 (2006.01.01); A61K 31/4985 (2006.01.01); A61P 35/00 (2006.01.01); C07D 277/82 (2006.01.01); C07D 417/12 (2006.01.01); A61K 9/48 (2006.01.01); A61K 9/20 (2006.01.01); A61P 25/14 (2006.01.01)
(19)CountryUS
(41)Date of publication of the application2020.10.31
(49)Date of publication of the translation of the validated European patent specification2025.02.28
(30)Priority201762584856 P, 2017.11.12, US; 201862717948 P, 2018.08.13, US
(74)Patent attorney(Procedură) CORCODEL Angela, Bd. Ştefan cel Mare nr. 134, Chişinău, Republica Moldova
(86)International applicationPCT/US2018/060232, 2018.11.11
(87)International publicationWO 2019/094851, 2019.05.16
Up
/Inventions/details/3706739